ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

denifanstat

Also written as “Denifanstat”, “ASC40” and “TVB-2640”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Acne Vulgaris · Glioblastoma · Neoplasms, led by 2 companies.

Drug pageTVB-2640: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 10, 202415 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sagimet Biosciences91 open or runningphase 3since Sep 10, 2024Aug 18, 2014Aug 2027phase 3 · NCT07863193
Ascletis Pharmaits history only61 open or runningphase 3since Oct 26, 2021Apr 14, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sagimet Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2014First study: phase 1 study in NeoplasmsFirst studyNCT02223247 · 180 enrolled · United States, United Kingdom
  2. Apr 24, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03938246 · 142 enrolled · United States, China
  3. May 20, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT04906421 · 168 enrolled · United States, Canada, Poland and more
  4. Jul 28, 2021Named denifanstatINNProposed as its International Nonproprietary Name in WHO's List 125 · before, TVB-2640
  5. Dec 12, 2022Phase 1 study in Healthy VolunteersNCT05657834 · 8 enrolled · United States
  6. Apr 17, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT05835180 · 48 enrolled · United States, Hungary
  7. Sep 10, 20242 phase 3 studies in Non-alcoholic Fatty Liver DiseaseNCT06692283, NCT06594523
  8. Oct 8, 2025Phase 1 study in HealthyNCT07216313 · 40 enrolled · United States
  9. Oct 2, 2026Phase 3 study in Acne VulgarisNCT07863193 · 800 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 3 study in Acne VulgarisNCT07863193

TargetBeta

FASN →read by rule
“An orally bioavailable fatty acid synthase (FASN) inhibitor, ”NCIt, by rule

Studies

All 9 Sagimet Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07863193Acne Vulgaris · United States3RecruitingAug 2027800
NCT07216313Healthy · United States1CompletedOct 20, 202540
NCT06692283Non-alcoholic Fatty Liver Disease3WithdrawnJun 20260
NCT06594523Non-alcoholic Fatty Liver Disease3WithdrawnDec 20300
NCT05835180Non-alcoholic Fatty Liver Disease · United States, Hungary1CompletedDec 18, 202348
NCT05657834Healthy Volunteers · United States1CompletedDec 21, 20228
NCT04906421Non-alcoholic Fatty Liver Disease · United States, Canada, Poland and more2CompletedOct 2, 2023168
NCT03938246Non-alcoholic Fatty Liver Disease · United States, China2CompletedOct 2, 2021142
NCT02223247Neoplasms · United States, United Kingdom1CompletedJun 2017180

How it is read

Names in the registry

  • “Denifanstat”, 3 entries
  • “ASC40”, 3 entries
  • “TVB-2640”, 3 entries
  • “ASC40 25mg”, 1 entry
  • “ASC40 50mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.